Eesti Energia will publish its 2026 Q1 financial results and interim report on 30 April. The investor call to present the results will take place on 30 April at 11:00 London time, 12:00 Frankfurt time, and 13:00 Tallinn time. The conference call will be held in English. To participate, please join via the following link. A Q&A session will follow the presentation. As the webinar time is limited, we encourage participants to share their questions with us in advance at investor@enefit.com The report and the investor call presentation will be made available in the morning of 30 April on the Eesti Energia Investor Relations website. The recording and transcript of the call will be published on the same page afterwards. Further information:Danel FreibergHead of Treasury and Financial Risk ManagementEesti Energia ASTel: +372 5594 3838E...

DIGITALIST GROUP PLC                    Stock Exchange Release 24.4.2026 at 9:00                                    Digitalist Group Plc’s Business Review, 1 January – 31 March 2026 January–March 2026 (comparable figures for 2025 in parentheses):Turnover: EUR 3.8 million (EUR 4.5 million), decrease of 14.0%. EBITDA: EUR -0.4 million (EUR -0.1 million), -10.6% of turnover (-3.0%). EBIT: EUR -0.5 million (EUR -0.3 million), -13.9% of turnover (-5.9%). Net income: EUR -1.3 million (EUR -1.0 million), -32.8% of turnover (-23.0%). Earnings per share (diluted and undiluted): EUR -0.45 (EUR -0.37).* Number of employees at the end of the review period: 120 (123), reduction of 2.4%.*The 2025 figures are presented on a comparable basis following the share consolidation on 15 August 2025. CEO’s review The first quarter of 2026 has been a challenging...

Vaisala Corporation        Interim Report January–March 2026        April 24, 2026, at 9:00 a.m. (EEST) Vaisala Corporation Interim Report January–March 2026: Industrial Measurements growth driving first quarter results This release is a summary of Vaisala’s Interim Report January–March 2026. The complete report is attached to this release as a pdf file. It is also available on the company website at https://www.vaisala.com/en/investors. First quarter 2026:        Orders received EUR 127.4 (121.4) million, increase 5%, in constant currencies 10% Order book at the end of the period EUR 197.2 (Dec 31, 2025: 185.8) million, increase 6% Annual recurring revenue* (ARR) EUR 58.2 (Dec 31, 2025: 57.1) million, increase 2% Net sales EUR 137.0 (135.6) million, increase 1%, in constant currencies 7% EBITA EUR 20.7 (20.5) million, 15.1 (15.1) %...

Period January – MarchOrder intake decreased by 18 per cent and amounted to MSEK 218 (267), Adjusted for currency effects, the order intake decreased by 10 per cent. Net sales in SEK decreased by 16 per cent and amounted to MSEK 218 (259) Adjusted for currency effects of MSEK 24 and an order of MSEK 16 which this year will be delivered in Q2 (last year in Q1), revenue amounted to MSEK 258, corresponding to un unchanged growth Operating profit amounted to MSEK 15.4 (23.0) Adjusted for non-recurring costs of MSEK 2.3, operating profit amounted to MSEK 17.7 (23.0) Profit before tax amounted to MSEK 15.7 (20.9) Net profit for the period amounted to MSEK 12.2 (15.8) Earnings per share amounted to 1.07 (1.38) SEKSignificant events during the quarterThe Board of Directors has decided to propose an unchanged dividend of SEK 1.50 (1.50)...

Flow Traders 1Q 2026 Trading Update Amsterdam, the Netherlands – Flow Traders Ltd. (Euronext: FLOW) announces its unaudited 1Q 2026 trading update. HighlightsFlow Traders recorded net trading income of €155.9m and total income of €157.7m in 1Q26, increases of 11.2% and 16.8% when compared to 1Q25, respectively. Both, Flow Traders’ ETP value traded and its total value traded increased by 27% year-on-year in 1Q26, to €644bn and €2,182bn respectively. Fixed operating expenses were €56.1m in the quarter, an increase of 10.5% when compared to 1Q25, driven by higher employee and technology expenses. Total operating expenses were €85.5m in 1Q26, an increase of 17.5% when compared to 1Q25, mostly due to higher variable employee expenses related to strong financial performance. EBITDA was €72.2m in the quarter, an increase of 15.9% when...

Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter revenue of MNOK 112 with corresponding EBITDA of MNOK 27. Sales and EBITDA are slightly better than in the same quarter last year, adjusted for currency effects. Strong sales volume of 1.520MT in quarter (+9%), offset by stronger NOK vs EUR and lower global metformin prices compared to same quarter last year. The net profit ended at MNOK 21.5 (MNOK 21.7) for the first quarter of 2026. While net cash position as of end of March was MNOK 6. “We are pleased with our first quarter result which is on par with a record strong 2025, adjusted for FX. 9% increase in sales volume shows that we are able to turn increased capacity and available volumes...

WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results. Full Year 2025 Financial Highlights:Total revenue for the year ended December 31, 2025 was $427,869 compared to $2,080,879 for the year ended December 31, 2024. Revenue in both periods is mainly animal health related. The Company is now focused on expanding its distribution and sales agent network for the revyve® product line in both Canada and the United States.Gross profit (loss) for the year ended December 31, 2025 was $(640) compared to gross profit of $872,096 for the year ended December 31, 2024. Gross profit in the current year was impacted by one-time sales and cost of sales adjustments related to the Company’s discontinued...

— Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 — — Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) — — On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 — — Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of 2026 — Antwerp, Belgium, April 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage...

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — The Federal Home Loan Bank of New York (“FHLBNY”) today released its unaudited financial highlights for the quarter ended March 31, 2026.    “Across the first quarter of 2026, Federal Home Loan Bank of New York members continued to rely on the certainty of our funding to help support their local lending activities,” said Randolph C. Snook, president and CEO of the FHLBNY. “Our ability to execute on our foundational liquidity mission also positions our cooperative to serve as a trusted community partner, as we allocated more than $22 million from this quarter’s earnings to fund our affordable housing and community development programs.” Highlights from the first quarter of 2026 include:Net income for the quarter was $153.9 million, a decrease of $1.8 million, or 1.2%, from net income...

Press Release Results Full Year 2025 REVENUES: €1,736 MILLION vs 1,865 million in 2024ADJUSTED EBITDA: €145 MILLION vs €109 million in 20241ADJUSTED EBITA: €76 MILLION vs €46 million in 2024FCF POSITIVE: €62 MILLION vs -€25 million in 2024 Paris (France) – April 23, 2026 – Vantiva (Euronext Paris: VANTI), a global technology leader in connectivity, announces its audited results for the year 2025. Estimated Operational results were published on March 27. The Board of Directors approved the consolidated financial statements on April 23, 2026. Audit procedures have been completed, and the audit reports are being issued.Full-year sales decreased by 7.0% to €1,736 million, largely due to USD weakness (-3.1% at constant exchange rates) and Video decline coupled with a soft Q4 due to a challenging YoY comparable and some component supply delays....